Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Chemo Pharma Laboratories Limited (506365) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Chemo Pharma Laboratories Limited ₹8.55, price ₹79.00, upside -89.2%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
CP
Thin data
Sep 24, 2026
Chemo Pharma Laboratories Limited
506365 · BSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹8.55 · Strongly overvalued (−89.2%)
!Quality 54/100
!Weak Growth
✓Highly profitable · 36.8% net margin (TTM)
!negative free cash flow
✓Ranks above peers (9/12)
!Moderate moat 60/100
!Evidence only low, so the estimate is less certain
Watch Chemo Pharma Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹17.85 – ₹150.65 · fair‑value band ₹5.64 – ₹10.69 · the ₹79.00 price screens above the ₹8.55 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Chemo Pharma Laboratories in your weekly email
Every Wednesday you see whether Chemo Pharma Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Chemo Pharma Laboratories Limited does not have significant operations. Previously, it was engaged in the finance and investment activities. The company was founded in 1942 and is based in Mumbai, India.
Stock analysis
Chemo Pharma Laboratories Limited (506365) currently trades at ₹79.00, while our model-based Fair Value estimate is ₹8.55, 89.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹5.64 (bear) to ₹10.69 (bull), the price of ₹79.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Chemo Pharma Laboratories Limited reported revenue of ₹5.3M in FY2026 versus ₹0 in FY2022. Reported net income was −₹119M in FY2026.
Key figures
Market cap ₹30.2M (≈ $314K) · P/E ratio 8.6 · P/S ratio 4.11 · EPS (TTM) ₹1.81 · Net margin 36.8% · Return on assets (EBIT) −133% · Operating margin 50.2% · Revenue (TTM) ₹7.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 46% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −89%, 506365 screens richer than that median.
Fair Value models
Bear ₹5.64
Fair Value ₹8.55
Bull ₹10.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.9203 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
₹4.30
₹5.76
₹8.60
51
All 1 models by family
Asset-Based
NCAV (Graham)
₹4.30
₹5.76
₹8.60
51
Notify me when 506365 reaches fair value
Put 506365 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
54/100
Of which business quality 47 · Market factors (momentum, volatility) 23
Profitability
5
Margins and returns on capital today
Quality Growth
50
Are margins and returns improving?
Cashflow
32
Earnings quality: real cash, not paper profit
Fin. Strength
51
Balance sheet, leverage, solvency risk
Investment
100
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
15
Price trend over the last 3–12 months (market factor)
52W Momentum
5
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
9/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
71.4% (2014) → −2,259.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Compare Chemo Pharma Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Chemo Pharma Laboratories Limited (506365) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹8.55 versus a price of ₹79.00, about −89% upside (overvalued).
What is the fair value of 506365?
Our model-based fair value for Chemo Pharma Laboratories Limited is ₹8.55 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹79.00.
What is the quality score of 506365?
Chemo Pharma Laboratories Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chemo Pharma Laboratories Limited (506365)?
Our model-based price target is the fair value of ₹8.55 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario ₹5.64, optimistic scenario ₹10.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Chemo Pharma Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹8.55, about −89% upside versus a price of ₹79.00 (overvalued). Cautious scenario ₹5.64, optimistic scenario ₹10.69. The calculation is refreshed regularly with new filings.
What is the revenue of Chemo Pharma Laboratories Limited (506365)?
Chemo Pharma Laboratories Limited reported trailing-twelve-month revenue of about ₹7.3M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Chemo Pharma Laboratories Limited (506365)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chemo Pharma Laboratories Limited it is ₹8.55 per share (as of Sep 24, 2026), against a price of ₹79.00. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Chemo Pharma Laboratories Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 506365 trades above its calculated fair value: price ₹79.00, fair value ₹8.55, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 506365?
No. The price is what the market pays today (₹79.00); the fair value is what the company's own numbers justify (₹8.55). For Chemo Pharma Laboratories Limited the two are ₹70.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chemo Pharma Laboratories Limited worth?
The market values Chemo Pharma Laboratories Limited at about ₹30.2M (market capitalisation, as of Sep 24, 2026). Per share that is ₹79.00; our models calculate a fair value of ₹8.55 per share.
What do the bullish and bearish scenarios say about 506365?
Our models span a range for Chemo Pharma Laboratories Limited: cautious scenario ₹5.64, base ₹8.55, optimistic ₹10.69 per share (as of Sep 24, 2026, price ₹79.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 506365?
Chemo Pharma Laboratories Limited trades at a price-to-earnings ratio of 8.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹8.55 is built from several models across several years. Other multiples: P/B 2.3, P/S 4.1, EV/EBITDA 7.5.
How far is 506365 from its 52-week high?
Chemo Pharma Laboratories Limited trades at ₹79.00, about 46% below its 52-week high of ₹145.75 and 11% above the low of ₹71.01 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹8.55 is for.
Which stocks are comparable to Chemo Pharma Laboratories Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chemo Pharma Laboratories Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹79.00, calculated fair value ₹8.55 (−89%), Quality Score 54/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 506365 calculated?
We run Chemo Pharma Laboratories Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹8.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Chemo Pharma Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chemo Pharma Laboratories Limited (506365)?
The closing price on Oct 1, 2026 was ₹79.00. Our model-based fair value is ₹8.55, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chemo Pharma Laboratories Limited right now?
The price sits above even our optimistic bull case (₹10.69). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹5.64 to ₹10.69) leaves room in how you read the outcome.
Key figures of Chemo Pharma Laboratories Limited
How large is the market capitalisation of Chemo Pharma Laboratories Limited (506365)?
The market capitalisation of Chemo Pharma Laboratories Limited is ₹30.2M (≈ $314K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chemo Pharma Laboratories Limited (506365)?
The price-to-sales ratio of Chemo Pharma Laboratories Limited is 4.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chemo Pharma Laboratories Limited (506365)?
Earnings per share at Chemo Pharma Laboratories Limited are ₹1.81 (price ÷ EPS = P/E 8.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Chemo Pharma Laboratories Limited (506365)?
The net margin of Chemo Pharma Laboratories Limited is 36.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Chemo Pharma Laboratories Limited (506365)?
On an EBIT basis the return on assets of Chemo Pharma Laboratories Limited is −133% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chemo Pharma Laboratories Limited (506365)?
The operating margin of Chemo Pharma Laboratories Limited is 50.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chemo Pharma Laboratories Limited (506365)?
Revenue at Chemo Pharma Laboratories Limited is growing −48.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chemo Pharma Laboratories Limited (506365)?
Earnings per share at Chemo Pharma Laboratories Limited are growing −43.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Chemo Pharma Laboratories Limited (506365) generate?
The free cash flow of Chemo Pharma Laboratories Limited is −₹106M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Chemo Pharma Laboratories Limited in the live analysis
One click puts Chemo Pharma Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.